Every Form 4 that Lucid Diagnostics Inc. (LUCD) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow LUCD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LUCD filings page.
Lucid Diagnostics Inc. director Dennis Matheis reported an open-market purchase of 245,000 shares of common stock. The weighted average purchase price was $1.0011 per share, with individual trade prices ranging from $0.9375 to $1.0200. Following these purchases, he directly owns 1,033,443 shares.
Lucid Diagnostics Inc. reported that Chief Executive Officer Aklog Lishan acquired 2,170,000 shares of common stock through a restricted stock grant under the company’s 2018 Equity Plan. The grant has a single vesting date of May 20, 2029 and is subject to forfeiture if the required service period is not completed.
Following this award, Lishan directly holds 3,636,627 shares of common stock. The transaction was recorded at a price of $0.00 per share, reflecting that it is an equity compensation grant rather than an open-market purchase.
Matheis Dennis reported acquisition or exercise transactions in this Form 4 filing.
Lucid Diagnostics Inc. director Dennis Matheis reported an equity award of 123,000 shares of common stock. These shares are structured as restricted stock granted under the company’s 2018 Equity Plan and were not purchased on the open market.
The restricted stock has a single vesting date of May 20, 2029 and is subject to forfeiture if the required service period is not completed. Following this grant, Matheis directly holds 788,443 shares of Lucid Diagnostics common stock.
White Debra reported acquisition or exercise transactions in this Form 4 filing.
Lucid Diagnostics Inc. director Debra White reported receiving a grant of 123,000 shares of common stock as a restricted stock award under the company’s 2018 Equity Plan. The award was granted at $0.00 per share and increases her directly held stake to 235,800 shares after the transaction.
The restricted stock has a single vesting date of May 20, 2029 and is subject to forfeiture if the required service period is not completed, meaning she must remain in service through that date for the shares to fully vest.
Sparks Ronald M reported acquisition or exercise transactions in this Form 4 filing.
Lucid Diagnostics director Ronald M. Sparks received an equity award of 123,000 shares of common stock on February 20, 2026. The shares were granted at a price of $0.00 per share as restricted stock under the company’s 2018 Equity Plan.
Following this grant, Sparks directly owns 320,460 shares of common stock. The restricted stock has a single vesting date of May 20, 2029 and is subject to forfeiture if the required service period is not completed, meaning he must remain in service through that date to retain the award.
SOKOLOV JACQUE J reported acquisition or exercise transactions in this Form 4 filing.
Lucid Diagnostics Inc. director Jacque J. Sokolov reported an equity award of 123,000 shares of Common Stock. The shares are restricted stock granted under the company’s 2018 Equity Plan and carry a single vesting date of May 20, 2029, subject to forfeiture if the required service is not completed.
After this grant, Sokolov directly holds 320,460 shares of Lucid Diagnostics common stock.
PALUMBO JOHN R reported acquisition or exercise transactions in this Form 4 filing.
Lucid Diagnostics Inc. director John R. Palumbo received a grant of 123,000 shares of common stock as a restricted stock award under the company’s 2018 Equity Plan. The award was granted at $0.00 per share and increases his directly held common stock to 338,000 shares.
The restricted stock has a single vesting date of May 20, 2029 and is subject to forfeiture if the required service period is not completed, meaning Palumbo must remain in the specified service role through that date for the shares to fully vest.
Lapidus Stanley reported acquisition or exercise transactions in this Form 4 filing.
Lucid Diagnostics Inc. director Stanley Lapidus received a grant of 123,000 shares of common stock as an equity award. The award was granted at no cash cost and increased his directly held shares to 337,392. The shares are restricted stock under the company’s 2018 Equity Plan with a single vesting date of May 20, 2029, and are subject to forfeiture if the required service period is not completed.
Lucid Diagnostics Inc. director James L. Cox reported an equity award of common stock. He acquired 123,000 shares of restricted stock at a grant price of $0.00 per share as a grant, award, or other acquisition under the company’s 2018 Equity Plan. These restricted shares have a single vesting date of May 20, 2029 and are subject to forfeiture if the required service period is not completed. Following this award, Cox directly holds a total of 405,120 shares of Lucid Diagnostics common stock.
Lucid Diagnostics Inc. reported that Chief Financial Officer Dennis M. McGrath acquired 470,000 shares of common stock through a restricted stock grant at a price of $0.00 per share. These shares vest in a single installment on May 20, 2029 and are subject to forfeiture if the required service period is not completed. Following this award, McGrath directly holds 1,813,569 shares of Lucid Diagnostics common stock.
Lucid Diagnostics Inc. reported that President and COO Shaun O'Neil acquired 620,000 shares of common stock through a restricted stock grant under the company’s 2018 Equity Plan. The restricted stock has a single vesting date of May 20, 2029 and is subject to forfeiture if the required service period is not completed. Following this award, O'Neil directly holds 1,446,763 shares of common stock.
Gordon Michael Adam reported acquisition or exercise transactions in this Form 4 filing.
Lucid Diagnostics Inc. reported that its General Counsel and Secretary, Gordon Michael Adam, received a grant of 300,000 shares of common stock on February 20, 2026. The award is structured as restricted stock that vests in full on May 20, 2029 and is subject to forfeiture if the required service period is not completed. Following this grant, Adam directly holds 1,000,000 shares of Lucid Diagnostics common stock.